BioLineRx (BLRX) Announces Presentation of Positive BL-8040 Phase 2a Data in AML
Tweet Send to a Friend
BioLineRx Ltd. (Nasdaq: BLRX) announced that the successful final results of BL-8040's Phase 2a clinical trial in relapsed or refractory ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
